HLA-DPB1 and chronic beryllium disease: In the chronic beryllium disease, the binding of beryllium to the HLA-DP molecules (facilitated by the presence of Glu69 and a negatively charged amino acid at P4 of the peptide and two other negatively charged amino acids in the groove) triggers a beryllium-specific polyclonal T-cell response leading to inflammation and tissue damage.